LBH589 Treatment for Refractory Clear Cell Renal Carcinoma

Inclusion Criteria: * Histologically documented metastatic or locally unresectable clear cell renal carcinoma. In patients with mixed histologies, the clear cell component must comprise \> 75% of the cancer. * Documented disease progression or intolerance while receiving treatment with: a) sunitinib, sorafenib, or both, and b) temsirolimus. * Maximum of 4 prior systemic regimens allowed and may include other targeted agents, immunotherapy and chemotherapy. * Measurable disease by RECIST criteria. * ECOG PS 0 or 1. * Laboratory values as follows: ANC \>= 1500/μL, Hgb \>= 9 g/dL, Platelets \>= 100,000/uL, AST/SGOT and ALT/SGPT \<= 2.5 x ULN or \<= 5.0 x ULN in patients with liver metastases, Creatinine \<= 2.0 mg/dL Or Calculated Creatinine Clearance \>= 50 ml/min, Albumin \>= 3 g/dL, Potassium \>= lower limit normal (LLN),Phosphorous \>= LLN, Calcium \>= LLN, Magnesium \> LLN * Women of childbearing potential must have a negative serum or urine pregnancy test performed within 7 days prior to start of treatment. * Life expectancy \> 12 weeks. * Accessible for treatment and follow-up. * All patients must be able to understand the nature of the study and give written informed consent prior to study entry. Exclusion Criteria: * Age \< 18 years of age. * Prior treatment with an HDAC inhibitor. * Impaired cardiac function * Ongoing therapy with antiarrhythmics or other medications associated with QTc prolongation. * Uncorrected hypokalemia or hypomagnesemia. * Uncontrolled hypertension or cardiac arrhythmias. * Active parenchymal brain metastases. Patients who have had brain metastases resected, or have received radiation therapy ending \> 8 weeks prior to study entry are eligible if they meet all of the following criteria: 1) residual neurologic symptoms \< grade 1, 2) no dexamethasone requirement, 3) follow-up MRI shows regression of lesions after treatment, with no new lesions appearing. * Active meningeal metastases. * Known diagnosis of human immunodeficiency virus (HIV) infection. * Unresolved diarrhea \> CTCAE grade 1. * Concomitant requirement for medication classified as CYP3A4 inducers or inhibitors. * Chemotherapy, investigational drug therapy, major surgery \< 4 weeks prior to starting study drug or patients that have not recovered from side effects of previous therapy. * Patient is \< 5 years free of another primary malignancy except if the other primary malignancy is not currently clinically significant or requiring active intervention, or if other primary malignancy is a basal cell skin cancer or a cervical carcinoma in situ. Existence of any other malignant disease is not allowed. * Concomitant use of any anti-cancer therapy or radiation therapy. * Pregnant or breast feeding or female of reproductive potential not using 2 effective methods of birth control. * Male patients whose sexual partners are women of childbearing potential not using effective birth control. * Patients with gastrointestinal (GI) tract disease, causing the inability to take oral medication, malabsorption syndrome, a requirement for intravenous (IV) alimentation, prior surgical procedures affecting absorption, uncontrolled inflammatory GI disease. * Other concurrent severe, uncontrolled infection or intercurrent illness * Abnormal thyroid function (TSH or free T4) detected at screening. Patients with known hypothyroidism who are stable on thyroid replacement are eligible.